Potential role of thymosin beta 4 in the treatment of nonalcoholic fatty liver disease
As a result of increased prevalence of obesity worldwide, non-alcoholic fatty liver disease (NAFLD) has become one of the most common causes of chronic liver disease. Although most NAFLD cases remain benign, some progress to end-stage liver diseases such as cirrhosis and hepatocellular carcinoma. Th...
Enregistré dans:
Auteurs principaux: | Yong Jiang, Tao Han, Zhi-Guang Zhang, Man Li, Feng-Xiang Qi, Ying Zhang, Ying-Lan Ji |
---|---|
Format: | article |
Langue: | EN |
Publié: |
KeAi Communications Co., Ltd.
2017
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/a2dc2abff5b64dabb16e2113912d964a |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Obesity and nonalcoholic fatty liver disease: current perspectives
par: Sarwar R, et autres
Publié: (2018) -
Liver biopsy in the quantitative assessment of liver fibrosis in nonalcoholic fatty liver disease
par: Gwyneth Shook Ting Soon, et autres
Publié: (2021) -
Serum iron and risk of nonalcoholic fatty liver disease and advanced hepatic fibrosis in US adults
par: Huan-Huan Yang, et autres
Publié: (2021) -
Circulating miRNA is a useful diagnostic biomarker for nonalcoholic steatohepatitis in nonalcoholic fatty liver disease
par: Tae Hyung Kim, et autres
Publié: (2021) -
Targeted delivery of thymosin beta 4 to the injured myocardium using CREKA-conjugated nanoparticles
par: Huang Z, et autres
Publié: (2017)